332 related articles for article (PubMed ID: 29050694)
1. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
2. How is the Ph-like signature being incorporated into ALL therapy?
Maese L; Tasian SK; Raetz EA
Best Pract Res Clin Haematol; 2017 Sep; 30(3):222-228. PubMed ID: 29050695
[TBL] [Abstract][Full Text] [Related]
3. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
Pui CH; Roberts KG; Yang JJ; Mullighan CG
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
[TBL] [Abstract][Full Text] [Related]
4. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
5. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.
Iacobucci I; Roberts KG
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34062932
[TBL] [Abstract][Full Text] [Related]
6. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
Wells J; Jain N; Konopleva M
Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
[TBL] [Abstract][Full Text] [Related]
7. Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises.
Izraeli S
Curr Opin Hematol; 2014 Jul; 21(4):289-96. PubMed ID: 24848770
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options.
Ofran Y; Izraeli S
Blood Rev; 2017 Mar; 31(2):11-16. PubMed ID: 27665024
[TBL] [Abstract][Full Text] [Related]
9. Ph-like acute lymphoblastic leukemia.
Tran TH; Loh ML
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):561-566. PubMed ID: 27913529
[TBL] [Abstract][Full Text] [Related]
10. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
11. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
12. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
14. The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.
Shiraz P; Payne KJ; Muffly L
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32235787
[TBL] [Abstract][Full Text] [Related]
15. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
16. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
[TBL] [Abstract][Full Text] [Related]
17. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
18. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
Loh ML; Zhang J; Harvey RC; Roberts K; Payne-Turner D; Kang H; Wu G; Chen X; Becksfort J; Edmonson M; Buetow KH; Carroll WL; Chen IM; Wood B; Borowitz MJ; Devidas M; Gerhard DS; Bowman P; Larsen E; Winick N; Raetz E; Smith M; Downing JR; Willman CL; Mullighan CG; Hunger SP
Blood; 2013 Jan; 121(3):485-8. PubMed ID: 23212523
[TBL] [Abstract][Full Text] [Related]
20. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]